Template:Cystitis medical therapy: Difference between revisions

Jump to navigation Jump to search
Gerald Chi- (talk | contribs)
No edit summary
Abdurahman Khalil (talk | contribs)
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
==Empiric Therapy for Acute Cystitis==
==Empiric Therapy for Acute Cystitis== <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from ''Clin Infect Dis. 2011;52(5):e103-20.''<ref name="Gupta-2011"<ref>{{Cite journal  | last1 = Gupta | first1 = K. | last2 = Hooton | first2 = TM. | last3 = Naber |first3 = KG. | last4 = Wullt | first4 = B. | last5 = Colgan | first5 = R. | last6 = Miller | first6 = LG. | last7 = Moran | first7 = GJ. | last8 = Nicolle | first8 = LE. | last9 = Raz | first9 = R. | title = International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. | journal = Clin Infect Dis | volume = 52 | issue = 5 | pages = e103-20 | month = Mar | year = 2011 | doi = 10.1093/cid/ciq257 |PMID = 21292654 }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>




Line 6: Line 6:
{| style="background: #FFFFFF;"
{| style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Acute Bacterial Uncomplicated Cystitis}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Acute Bacterial Uncomplicated Cystitis}}
|-
|-
Line 29: Line 29:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | '''''OR''''' '''''▸ [[Beta-lactam|β-lactam]] agents for 3-7 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | '''''OR''''' '''''▸ [[Beta-lactam|β-lactam]] agents for 3-7 days'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |  ▸'''''[[Amoxicillin-clavulanate]]  500/125 mg PO q8h or 875/125 mg PO q8h'''''<br>OR<br>▸'''''[[Cefdinir]]  300 mg PO q12h or 600 mg PO q24''''' <br>OR<br>'''''[[Cefaclor]]  250-500 mg PO q8h'''''<br>OR<br>▸'''''[[Cefpodoxime proxetil]]  100-200 mg PO q12h'''''<br>OR<br>'''''[[Cephalexin]]250-500 mg PO q6h <small> not studied well but effective</small>.'''''  
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |  ▸'''''[[Amoxicillin-clavulanate]]  500/125 mg PO q8h or 875/125 mg PO q8h'''''<br>OR<br>▸'''''[[Cefdinir]]  300 mg PO q12h or 600 mg PO q24''''' <br>OR<br>'''''[[Cefaclor]]  250-500 mg PO q8h'''''<br>OR<br>▸'''''[[Cefpodoxime proxetil]]  100-200 mg PO q12h'''''<br>OR<br>'''''[[Cephalexin]]250-500 mg PO q6h <small> not studied well but effective</small>.'''''
|-
|-
|}
|}
Line 36: Line 36:
{| style="background: #FFFFFF;"
{| style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Complicated/Catheter Associated Cystitis}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Complicated/Catheter Associated Cystitis}}
|-
|-
Line 57: Line 57:
{| style="background: #FFFFFF;"
{| style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 500px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|Acute Cystitis in Pregnancy}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|Acute Cystitis in Pregnancy}}
|-
|-

Latest revision as of 19:24, 26 February 2014

==Empiric Therapy for Acute Cystitis== Adapted from Clin Infect Dis. 2011;52(5):e103-20.[1]


Acute Bacterial Uncomplicated Cystitis
Preferred Regimen
Nitrofurantoin 100 mg PO q12h × 5 days
OR
TMP 100 mg PO q12h ×3 days
OR
Fosfomycin 3 gm PO single dose
OR If resistence<20% or if used for UTI >3 months
TMP-SMX ‡ 1 DS tab PO q12h × 3 days
OR Not FDA approved but used in some European countries
Pivmecillinam 400 mg PO q12h 3-7 days
Alternative Regimen
Fluoroquinolones for 3 days
Ofloxacin 200–400 mg PO bid
OR
Ciprofloxacin 250 mg bid PO or Cipro XR 500 mg q24h
OR
Levofloxacin 250–750 mg PO q24
OR β-lactam agents for 3-7 days
Amoxicillin-clavulanate 500/125 mg PO q8h or 875/125 mg PO q8h
OR
Cefdinir 300 mg PO q12h or 600 mg PO q24
OR
Cefaclor 250-500 mg PO q8h
OR
Cefpodoxime proxetil 100-200 mg PO q12h
OR
Cephalexin250-500 mg PO q6h not studied well but effective.
Complicated/Catheter Associated Cystitis
Preferred Regimen
Mild Infection
Levofloxacin 750 mg PO q24 × 5 days
Delayed Response
Levofloxacin 750 mg PO q24 × 10-14 days
After Catheter Removal
Levofloxacin 750 mg PO q24 × 3 days
Acute Cystitis in Pregnancy
Preferred Regimen
Nitrofurantoin 100 mg PO q12h × 3-5 days
OR
Fosfomycin 3 g PO single dose
OR
Amoxicillin-clavulanate 500/125 mg PO q12h × 3-5 days
OR
Amoxicillin 500 mg PO q12h × 3-5 days
OR
Cephalexin 500 mg PO q12h × 3-5 days
OR
TMP-SMX DS 1 tab PO q12h × 3-5 days
avoid in first trimester(TMP) and third trimester (SMX).
  1. Gupta, K.; Hooton, TM.; Naber, KG.; Wullt, B.; Colgan, R.; Miller, LG.; Moran, GJ.; Nicolle, LE.; Raz, R. (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin Infect Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654. Unknown parameter |month= ignored (help)